Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone. (2022)

• Record Type: Journal Article
• Authors: Marcos, Luis A.; Leung, Annie; Kirkman, Laura; Wormser, Gary P.
• Is Part Of: IDCases. Volume 27(2022)
• Publication Date: 2022
• Subjects: Tafenoquine -- Babesiosis -- Babesia microti -- Rituximab -- Antibiotic resistance; Communicable diseases -- Periodicals; Communicable Diseases -- Case Reports; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; 616.9
• DOI: 10.1016/j.idcr.2022.e01460
• Languages: English
• ISSNs: 2214-2509

Abstract

Abstract: Tafenoquine is a highly effective treatment for Babesia microti infections in animal models. An immunocompromised patient infected by a strain of B. microti that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.